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OBJECTIVE—We examined the effect of the vasoactive agents
carbon monoxide (CO) and nitric oxide (NO) on the phosphor-
ylation and intracellular redistribution of vasodilator-stimulated
phosphoprotein (VASP), a critical actin motor protein required
for cell migration that also controls vasodilation and platelet
aggregation.
RESEARCH DESIGN AND METHODS—We examined the
effect of donor-released CO and NO in endothelial progenitor
cells (EPCs) and platelets from nondiabetic and diabetic subjects
and in human microvascular endothelial cells (HMECs) cultured
under low (5.5 mmol/l) or high (25 mmol/l) glucose conditions.
VASP phosphorylation was evaluated using phosphorylation
site-speciﬁc antibodies.
RESULTS—In control platelets, CO selectively promotes phos-
phorylation at VASP Ser-157, whereas NO promotes phosphory-
lation primarily at Ser-157 and also at Ser-239, with maximal
responses at 1 min with both agents on Ser-157 and at 15 min on
Ser-239 with NO treatment. In diabetic platelets, neither agent
resulted in VASP phosphorylation. In nondiabetic EPCs, NO and
CO increased phosphorylation at Ser-239 and Ser-157, respec-
tively, but this response was markedly reduced in diabetic EPCs.
In endothelial cells cultured under low glucose conditions, both
CO and NO induced phosphorylation at Ser-157 and Ser-239;
however, this response was completely lost when cells were
cultured under high glucose conditions. In control EPCs and in
HMECs exposed to low glucose, VASP was redistributed to
ﬁlopodia-like structures following CO or NO exposure; however,
redistribution was dramatically attenuated under high glucose
conditions.
CONCLUSIONS—Vasoactive gases CO and NO promote cy-
toskeletal changes through site- and cell type–speciﬁc VASP
phosphorylation, and in diabetes, blunted responses to these
agents may lead to reduced vascular repair and tissue perfusion.
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T
he gaseous signal molecules nitric oxide (NO)
and carbon monoxide (CO) exert multiple mod-
ulatory actions in regulating vascular function.
While NO effects have been recognized for over
a decade, similar vasoregulatory action of CO was estab-
lished only recently. CO is generated by heme oxygenase
(HO)-1 under a wide variety of conditions (e.g., cell
exposure to such stressors as hypoxia, growth factors, and
cytokine stimulation) that activate the enzyme (1,2). Un-
like its highly reactive cognate NO, which participates in
multiple redox reactions, CO is a relatively stable gas that
exhibits extraordinary afﬁnity for heme centers (3–5). Like
NO, the signaling effects of CO rely in part on its ability to
form a complex with the heme moiety of soluble guanylate
cyclase (sGC), stimulating the synthesis of the diffusible
second messenger guanosine 35-cyclic monophosphate
(cGMP) (6). The sGC/cGMP pathway plays a critical role
in mediating the effects of CO on vascular relaxation and
inhibition of platelet aggregation and coagulation (7,8).
A recently recognized property of NO is its cell type–
speciﬁc facilitation or inhibition of cell migration (9), a
complex process involving molecular-mechanical events
that depend on extracellular signaling, actin-based motil-
ity, and cell adhesion. Endothelial progenitor cells (EPCs)
differentiate into endothelial cells whose function in vas-
cular repair depends on chemokine- and growth factor–
directed cell migration. The role of EPCs in endothelial
repair is supported by their ability to inhibit development
of atherosclerosis (10,11) and intimal hyperplasia (12),
while still promoting beneﬁcial angiogenesis. We previ-
ously demonstrated the central role of the actin cytoskel-
eton in EPC migration (13), and our ﬁndings suggest that
NO has a critical function within EPCs, where it regulates
the distribution of vasodilator-stimulated phosphoprotein
(VASP). The latter plays a pivotal role in promoting actin
ﬁlament elongation at the leading edge by forming an
active molecular motor complex that propels motility (14).
VASP contains three distinct phosphorylation sites (Ser-
157, Ser-239, and Thr-278), the ﬁrst of which is preferen-
tially phosphorylated by cAMP-dependent protein kinase
(PKA) and the second by cGMP-dependent protein kinase
(PKG). Although the exact roles of phosphorylated resi-
dues in VASP have not completely been elucidated, one
idea is that a high 3,5-cyclic AMP (cAMP)-to-cGMP ratio
promotes VASP-activated actin ﬁlament elongation,
whereas a low cAMP-to-cGMP ratio favors ﬁlament cap-
ping and loss of motility (15). The following factors are
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2488 DIABETES, VOL. 57, SEPTEMBER 2008known to inﬂuence VASP phosphorylation: intracellular
localization in focal adhesions, ﬁlopodia, and lamellipo-
dial; accessibility of phosphorylation sites in VASP that is
complexed with other proteins; availability of speciﬁc
protein kinases and/or phosphoprotein phosphatases; and
the respective activators and inhibitors of these kinases
and phosphatases (16). We previously reported that the
reduced bioavailability of NO in diabetic individuals pre-
vents VASP redistribution, resulting in the inability of
EPCs to form proper cytoskeletal extensions (13). We also
showed that the EPC chemoattractant stromal cell–de-
rived factor-1 (SDF-1) transcriptionally activates HO-1 via
the atypical protein kinase C (PKC)- isoform generating
CO, which in turn can phosphorylate VASP in endothelial
cells (17).
Because PKG and PKA catalyze VASP phosphorylation,
and because the latter is thought to control VASP’s sub-
cellular distribution and function (13), we directly com-
pared the effects of NO and CO on VASP phosphorylation
and redistribution in cells typically known to be dysfunc-
tional in diabetes, namely platelets, EPCs, and microvas-
cular endothelial cells. We demonstrate that both CO and
NO regulate VASP phosphorylation and that pretreatment
with either agent stimulates migration toward SDF-1. We
also show that normal platelets display a modest response
to exogenous CO stimulation but a greater response to NO
treatment. In contrast, diabetic platelets are not respon-
sive to either CO or NO treatment (data not shown).
Culturing microvascular endothelial cells at high glucose
concentrations also results in reduced VASP phosphoryla-
tion. These novel ﬁndings suggest that CO regulates
VASP phosphorylation and vascular cell migration un-
der conditions of reduced NO bioavailability, as ob-
served in diabetes.
RESEARCH DESIGN AND METHODS
Cell culture. Human lung microvascular endothelial cells (HMECs) (LONZA,
Walkersville, MD) were cultured to 80% conﬂuency in EGM-2 MV medium
(LONZA) in 5.5 or 25 mmol/l glucose for 1 week. Cells were then incubated
overnight in EBM-2 supplemented with 2% fetal bovine serum. Fresh medium
(EBM-2  2% fetal bovine serum) was added on the following day, and CO- or
NO-containing medium was added to the designated samples for 1 or 15 min
at 37°C, as described below.
Isolation of platelets. Peripheral blood from healthy and diabetic volunteers
giving informed consent under a protocol approved by the institutional review
board was collected in cell preparation tubes (CPTs) with heparin (BD
Biosciences, San Jose, CA), and platelets were isolated using Opti-Prep
(Axis-Shield PoC, Oslo, Norway), as recommended by the manufacturer.
EPC culture. Peripheral blood from healthy and diabetic volunteers was then
collected into CPTs (BD Biosciences), and the EPCs were freed of the
mononuclear cells using an Endocult medium kit (Stem Cell Technologies,
Vancouver, CA) according to the manufacturer’s protocol, as previously
described (13).
Immunohistochemistry. EPCs were cultured onto ﬁbronectin-coated dishes
with Endocult stem cell liquid media until colonies formed. These cells were
then treated for 15 min or 4 h with 100 mol/l diethylenetriamine (DETA)-NO
(Sigma-Aldrich, St. Louis, MO) in water or 10 mol/l CO-donor Ru(II)(CO)3Cl2
(Sigma-Aldrich) in DMSO. Control samples were treated with vehicle. At the
end of the treatment, medium was removed and cells were ﬁxed overnight at
4°C in 4% paraformaldehyde in PBS, supplemented with calcium and magne-
sium ions, and adjusted to pH 7.4.
Cells were then washed in PBS and permeabilized with 0.1% Triton X-100
for 30 min at room temperature. After washing the samples an additional three
times in PBS, cells were treated with 10% normal goat serum–1% BSA in PBS
f o r1ha troom temperature to block nonspeciﬁc antigens. Cells were then
incubated with 5 g/ml mouse anti-VASP antibody (BD Biosciences) in 5%
normal goat serum overnight at 4°C and then with ﬂuorescein isothiocyanate
(FITC)-labeled goat anti-mouse IgG1 (1:250 dilution) (Southern Biotech,
Birmingham, AL) in 5% normal goat serum for1ha troom temperature.
Samples were then washed, dried, and mounted with 4,6-diamino-2-phenylin-
dole (DAPI) (Vectashield; Vector Laboratories, Burlingame, CA) to label
nuclear DNA. Samples were examined by ﬂuorescence microscopy (Nikon
Eclipse TE200) using a Nikon Plan-ﬂuor 40 (NA  1.30) oil objective and a
ﬂuorescein ﬁlter set (520  2 nm). Micrographs were captured using a SPOT
digital camera 0.60X HRD06-NIK (Diagnostic Instruments, Sterling Heights,
MI) and processed using SPOT Advanced software Version 2.2.1 for Windows.
Fluorescence-activated cell sorting. Peripheral blood was collected into
CPTs (BD Biosciences) and centrifuged to obtain the mononuclear cell
fraction, from which CD34
 cells were isolated using a CD34
 isolation kit
(Stem Cell Technologies, Vancouver CA). Brieﬂy, 2  10
7 cells were
incubated with a CD34
 selection cocktail for 15 min, and 50 l magnetic
nanoparticles was then added and incubated for another 10 min. The
suspension volume was increased to 2.5 ml, and the particle-bound CD34

cells were concentrated on the tube’s inner surface with the aid of a magnet.
The supernatant was decanted, and the remaining CD34
 cells were resus-
pended in RPMI culture media (Cellgro, Herndon, VA).
The cells were then treated with 100 mol/l on DETA-NO (Sigma-Aldrich)
for either 15 min or4hi naC O 2 incubator. Following treatment, the CD34

cells were permeabilized using a cytoﬁx/Cytoperm kit (BD Biosciences) and
blocked with 10% normal human serum (Jackson Immuno Research labs, West
Grove, PA), and 10 g antiphospho-VASP (Upstate Signaling, Lake Placid, NY)
was added to the cells, followed by 30-min incubation on ice. The cells were
then washed with PBS and incubated with 23 g FITC-conjugated goat
anti-mouse (Jackson Immuno Research labs, West Grove, PA), and again
incubated on ice for 30 min. The resulting cells were washed in PBS and
analyzed by ﬂuorescence-activated cell sorting (FACS). Anti-GFP (Molecular
probes, Carlsbad, CA) was used as an isotype control.
Preparation of DETA-NO and Ru(II)(CO)3Cl2 donors. The half-lives for
NO and CO release from DETA-NO and Ru(II)(CO)3Cl2 are greatly different,
resulting in the almost immediate release of CO but very slow release of NO.
Therefore, to assure that cells were exposed to comparable concentrations of
NO and CO, we ﬁrst calculated the amount of CO released at 1 and 15 min
using the integrated rate law: [CO donor]t/[CO donor]initial  exp (kCOt),
where [CO donor]t and [CO donor]initial are the CO donor concentrations at
time t and, initially, kCO is the ﬁrst-order rate constant for CO release, and t is
the incubation period. We then used the corresponding rate law, i.e., [NO
donor]t/[NO donor]initial  exp (kNOt) to determine the time needed to obtain
an extent of NO release comparable with that observed with CO donor in 1
and 15 min. The CO and NO donor rate constants kCO and kNO of 0.07 min 
1 and 0.0006 min  1, respectively, were determined based on the published
half-lives of 10 min for Ru(II)(CO)3Cl2 (18) and 18 h for DETA-NO (19). In our
experiments, we therefore separately preincubated the NO donor in culture
medium in a sealed tube for the calculated NO times, and then transferred an
appropriate aliquot to the cell. Because the partial pressure exerted by the
released NO and CO is far below the solubilities in aqueous solution, and
because the 1- and 15-min exposure times were short, there was no need to
maintain treated cells in a sealed culture dish.
Immunoblot. Following treatment with either the CO or NO donor, the
CD34
 cells or platelets were washed with PBS and lysed with lysis buffer
(Cell Signaling, Danvers, MA) containing protease (catalog no. P8340l Sigma-
Aldrich) and phosphatase inhibitors (catalog no. P2850; Sigma-Aldrich).
Protein was quantiﬁed in each sample using a commercially available BCA kit
(Pierce, Rockford, IL), and 50 g was applied to each well above the
polyacrylamide gel (7.5%) (Criterion; Biorad Laboratories, Richmond, CA) at
120 V for 20 min, followed by 140 V for 65 min. Samples were run in duplicate
for later detection of the two phosphorylated VASP (pVASP) isoforms. The
separated proteins were transferred to a nitrocellulose membrane (Biorad
Laboratories) in a semidry transblot apparatus (Biorad Laboratories). The
membranes were blocked in Tris-buffered saline (TBS) containing 5% milk and
0.05% Tween-20 (Sigma-Aldrich) for1ha troom temperature. For the
detection of pVASP isoforms, the membranes were incubated at 4°C overnight
with either a mouse monoclonal anti-pVASP Ser-239 antibody (Upstate Cell
Signaling Solutions, Lake Placid, NY) or a rabbit polyclonal anti-pVASP
Ser-157 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), both at a 1:200
dilution. Blots were then washed with 5% milk for 5 min and incubated with
a 1:2,000 dilution of either a horseradish peroxidase (HRP)-conjugated anti-
mouse antibody (Sigma-Aldrich) or an anti-rabbit (Santa Cruz Biotechnology)
for 1 h at room temperature. After incubation with the secondary antibody, the
membranes were washed twice with TBS containing 0.05% Tween-20 for 5
min, followed by two additional 10-min washes with TBS. Protein bands were
visualized with enhanced chemiluminescence using a commercial Western
blot detection kit (Amersham Biosciences, Amersham, U.K.) and pVASP levels
were quantiﬁed using Scionimage software (Scion, Frederick, MD). Standard
molecular weight markers (Biorad Laboratories) served to verify the molec-
ular mass of pVASP (50 kDa).
After pVASP detection, the membranes were reprobed for VASP using a
1:200 dilution of a goat anti-VASP antibody (Santa Cruz Biotechnology) and
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(Sigma-Aldrich), followed by HRP-conjugated anti-goat (Santa Cruz Biotech-
nology) and anti-mouse IgG antibody (Sigma-Aldrich), both at 1:2,000 dilution,
and were visualized by enhanced chemiluminescence. Standard molecular
weight markers served to verify the 42-kDa molecular mass of 	-actin.
In-cell Western analysis. CD34
 cells were cultured in deﬁned serum-free
medium (StemSpan SFEM; StemCell Technologies, Vancouver, Canada) to
obtain an optimal number of cells. For CD34
 cell proliferation and expan-
sion, without differentiation, we used 1 ml StemSpan SFEM supplemented
with a cytokine cocktail (100 ng/ml ﬂt3 ligand, 100 ng/ml stem cell factor, 20
ng/ml interleukin-3, and 20 ng/ml interleukin-6; StemCell Technologies) and 50
ng/ml thrombopoietin (R&D Systems, Minneapolis, MN). After determining
cell number with a hemocytometer (Hausser Scientiﬁc, Horsham, PA), 10,000
cells were transferred to each well in a 96-well plate (BD Falcon, San Jose,
CA). After incubation with/without CO or NO donor, cells were ﬁxed with 4%
paraformaldehyde for 20 min at room temperature and then harvested by
centrifugation. After removing the ﬁxation solution, cells were permeabilized
with 0.1% Triton X-100 in PBS and blocked with LI-COR Odyssey blocking
buffer (LI-COR Biosciences, Lincoln, NE) for 1.5 h at room temperature with
moderate shaking. Blocking buffer was removed by aspiration, and the cells
were incubated with 50-l volume of diluted primary antibody at 4°C
overnight in a cold room. Cells were then washed four times for 5 min in PBS
containing 0.1% Tween-20 (Fisher Scientiﬁc, Pittsburgh, PA) and incubated
with diluted secondary antibody. After 1-h incubation, cells were washed four
times (5 min each) with PBS containing 0.1% Tween-20, followed by ﬁnal
washing in PBS to remove excessive detergent. The 96-well plate was then
scanned in the appropriate channels using an Odyssey infrared imaging
system (LI-COR Biosciences). Relative quantiﬁcation was normalized and
readjusted in cell number from well to well using DNA staining.
Statistical analysis. All reported data are expressed as the mean  SEM and
were obtained from at least three independent experiments. Student’s t test
and ANOVA with Student-Newman-Keuls posttest were used to compare the
data.
RESULTS
The choice of the technique used (e.g., standard Western
blotting, In-Cell Western analysis, and FACS) for these
studies was largely governed by the number of cells
available for analysis. Because CD34
 cells represented

1% of circulating mononuclear cells, In-Cell Western
(low sensitivity) and FACS (higher sensitivity) analyses
were the methods of choice; however, for more abundant
cells such as endothelial cells, standard Western blotting
was sufﬁcient. All the phosphorylation studies on EPCs
were performed after 15 min of treatment. We then tested
whether a shorter treatment (1 min) could still elicit a
signiﬁcant migratory response.
We therefore pretreated human CD34
 EPCs for 1 and 15
min with medium containing NO or freshly generated CO,
followed by SDF-1 stimulation (13), and then assessed cell
migration using Boyden chambers. As demonstrated in Fig. 1,
both CO and NO treatment resulted in increased EPC migra-
tion to SDF-1, although a more robust response was ob-
served with NO at 1 min.
Because VASP is a key component of the actoclampin
molecular motors responsible for actin-based cell motility
(14,20), and because VASP was originally identiﬁed as a
major substrate for cGMP-stimulated protein kinase in
platelets and endothelial cells (21), we investigated
whether NO and CO elicited similar effects on VASP
phosphorylation and its mobilization to the leading edge of
motile cells. VASP function appears to be chieﬂy regulated
by phosphorylation at Ser-157 and Ser-239, and the avail-
ability of phosphorylation site-speciﬁc antibodies provides
an unambiguous way to deﬁne both the sites and extents
of signal molecule–activated VASP phosphorylation. We
therefore incubated CD34
 cells for 15 min in the presence
of NO or CO already liberated from their respective
donors. As shown in Fig. 2, NO treatment routinely in-
creased the extent of VASP phosphorylation at Ser-239,
whereas CO treatment consistently increased the extent of
Ser-157 phosphorylation in these cells.
To conﬁrm that the differential effects of CO and NO are
not limited to CD34
 cells, we also examined platelets,
which are a rich source of VASP and are the cells wherein
VASP phosphorylation is best characterized (22). In plate-
lets exposed to either NO or CO for 1- and 15-min periods,
we found that CO treatment caused a modest yet signiﬁ-
cant VASP phosphorylation at Ser-157, whereas NO treat-
ment signiﬁcantly increased VASP phosphorylation at Ser-
157 with maximum response at 1 min and at Ser-239 with
maximum effect at 15 min (Fig. 3). These ﬁndings suggest
that CO and NO elicit markedly different VASP phosphor-
ylation responses in platelets and CD34
 cells.
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FIG. 1. CO or NO treatment of EPCs stimulates migration. Because the
rate constants for CO release from Ru(II)(CO)3Cl2 dimer and for NO
release from DETA-NO are so disparate (RESEARCH DESIGN AND METHODS),
experiments with the NO donor required prior incubation for times
sufﬁcient to release equivalent concentrations of NO and CO. Accord-
ingly, EPCs (obtained from healthy human subjects) were treated with
10 mol/l Ru(II)(CO)3Cl2 dimer (CO donor) for 1 and 15 min, thereby
generating 0.6 and 6.5 mol/l CO, respectively. For the NO experi-
ments, 100 mol/l DETA-NO was ﬁrst incubated in a sealed tube for 2
and 28 h (based on the calculated time required to generate 0.6 and 6.5
mol/l NO, respectively), and then combined with EPC for 1 and 15
min, respectively. Cell migration in response to SDF-1 was subse-
quently assessed in a Boyden chamber. Representative results from at
least three independent experiments are shown. Values represent
means  SD. *P < 0.05. RFU, relative ﬂuorescence units.
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FIG. 2. Time course of NO- or CO-stimulated VASP phosphorylation at
Ser-157 and Ser-239. CD34
 cells were incubated for 15 min in the
presence of either 6.5 mol/l CO or NO (see legend to Fig. 1 for
details), and protein extracts were analyzed by In-Cell Western (see
RESEARCH DESIGN AND METHODS). Note that exposure of these cells to NO
resulted in increased VASP phosphorylation at Ser-239, whereas CO
increased phosphorylation at Ser-157. Representative results from
four independent experiments are shown. Values represent means 
SD. Reported P values indicate signiﬁcance between the treated and
the corresponding untreated sample. RFU, relative ﬂuorescence units.
REDUCED VASP PHOSPHORYLATION BY CO AND NO IN DIABETES
2490 DIABETES, VOL. 57, SEPTEMBER 2008Because VASP resides on the cytoplasmic face of the
leading edge in motile cells (23), and because VASP
phosphorylation is believed to control its interactions with
VASP-docking proteins like vinculin, zyxin, and migﬁlin,
we next examined the effects of donor-generated NO and
CO on the redistribution of VASP in microvascular endo-
thelial cells growing while ﬁrmly adhered to ﬁbronectin-
coated culture dishes. Under basal conditions (i.e., no NO
or CO), VASP was mainly localized along the sides of actin
ﬁlaments found throughout the peripheral cytoplasm (Fig.
4A and B). However, following a 15-min exposure to CO,
VASP redistributed to the leading edge of advancing
microvascular endothelial cells (Fig. 4C and D). VASP
redistribution was also observed when these cells were
incubated with NO (Fig. 4E and F).
In as much as diabetes-associated vascular dysfunction
is frequently attributed, at least in part, to reduced levels
of bioavailable NO, we sought to determine whether
diabetes impacted the NO and CO effects on VASP phos-
phorylation within cell types typically affected by diabetes.
We treated platelet samples from diabetic individuals with
NO or CO under the same conditions used in Fig. 1 and
observed no change in VASP phosphorylation, at either
Ser-157 or Ser-239 (data not shown). In Fig. 5, VASP
phosphorylation is shown for two diabetic patients and
one nondiabetic control subject. Patient 1 had type 2
diabetes of 5 years duration and excellent glycemic con-
trol (A1C 6.4%), while patient 2 had type 1 diabetes of 48
years duration and poor glycemic control (A1C 11.3%). A
different pattern was observed in the diabetic CD34
 cells,
where NO treatment stimulated phosphorylation at VASP’s
Ser-239 to a signiﬁcantly less extent, when compared with
the nondiabetic control cells. However, we observed con-
siderable patient-to-patient variation in the degree of the
response but all with the same pattern.
Notably, compared with control cells grown in low-
glucose medium, exposure of microvascular cells to con-
ditions mimicking aspects of diabetes (e.g., culturing these
cells for 1 week in high-glucose medium) resulted in a
failure of NO and CO to elicit changes in either VASP
redistribution to the leading edge of the cells, as shown by
immunoﬂuorescence (compare Figs. 4 and 6), or phos-
phorylation at Ser-157 or Ser-239, as detected by standard
Western blot analysis (Fig. 7).
DISCUSSION
Understanding the regulation of endothelial cell migration
in response to chemokines has proven to be a daunting
task that requires the investigation of a manifold of factors
known to affect chemotaxis (e.g., chemokine sensing by
receptor-mediated signaling, cellular locomotion by actin-
based molecular motors, and even the cell’s energy sta-
tus). Previous studies from our laboratory on CD34
 EPCs
showed that diabetic EPCs have reduced intracellular NO
concentration as well as a concomitantly reduced migra-
tory capability. We found that, when pretreated with an
NO donor, cell migration can be restored (13), and we
further demonstrated that this exogenous NO exposure
resulted in enhanced diabetic cell migration, with atten-
dant changes in phosphorylation of the actin cytoskeletal
protein VASP (13).
Given the robust nature of the vasodilator gases CO and
NO in modulating vascular function, we focused on the
following questions: Can CO sufﬁce in place of NO in
promoting vascular cell migration? If so, do NO and CO
exert their signaling effects on the same downstream
phosphorylation target(s)? In this study, we demonstrate
that CO can regulate VASP phosphorylation and in turn
alter cell migration. We also directly compare the CO
effects to those of NO in EPCs, platelets, and microvascu-
lar endothelial cells. Our studies demonstrate that both
vasoactive gases promote cytoskeletal changes through
site- and cell type–speciﬁc VASP phosphorylation; how-
ever, these responses to NO and CO are blunted in
diabetes and may be responsible for reduced vascular
repair and tissue perfusion (24,25).
The actoclampins are the force-generating motors re-
sponsible for actin-based cell crawling and vesicle motility
(14). Each of these membrane surface–bound molecular
motors consists of an actin ﬁlament plus-end tracking
protein called a clampin (e.g., VASP, N-WASP [neural
Wiskott–Aldrich syndrome protein], formins, etc.) and its
actin ﬁlament partner. The energy for force production
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FIG. 3. Signal-mediated platelet VASP phosphorylation indicates low responsiveness to CO (A) but robust response to NO (B). Platelets (isolated
from human peripheral blood as described above) were treated with either CO or NO as described in the legend to Fig. 1. Platelets were then
extracted with lysis buffer, and equal quantities of total protein were loaded and separated by SDS-polyacrylamide gel electrophoresis, followed
by transfer to nitrocellulose for immunoblotting with VASP phosphorylation site-speciﬁc antibodies. Corrections for variations in gel loading
were made by normalizing band intensities to those for -actin. Representative results from at least three independent experiments are shown.
Values represent means  SD. *P < 0.05. RFU, relative ﬂuorescence units.
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ﬁlament’s penultimate actin-ATP subunits, thereby pro-
moting clampin release, translocation, and rebinding to
terminal actin-ATP subunits. Before the active motor
complex is assembled, clampins must be recruited to the
membrane surface, where they dock at motility sites at the
tips of ﬁlopodia and lamellipodia as well as in the focal
adherens complex. Rottner et al. (23), for example,
showed that VASP not only colocalizes to adhesion sites
with the adaptor proteins vinculin and zyxin, but is also
recruited to the tips of lamellipodia in amounts that are
directly proportional to the rate of lamellipodial protru-
sion. Tokuo and Ikebe (26) further showed that myosin X
speciﬁcally transports VASP and other members of the
Ena/VASP clampin protein family to the leading edge,
where VASP then binds to a membrane docking protein
such as vinculin, zyxin, or migﬁlin (27,28). Only then can
the actoclampin motor assemble and generate the forces
needed for cell migration. When viewed from this perspec-
tive, VASP phosphorylation may affect the recruitment by
myosin X, VASP docking with membrane components,
and/or VASP-mediated formation of an active motor that
can propel cell crawling. Moreover, as cells stop moving,
VASP is known to redistribute to other intracellular sites.
Benz et al. (29), for example, showed that VASP interacts
with II-spectrin in endothelial cells and that PKA-medi-
ated VASP phosphorylation at Ser-157 inhibits this binding
interaction. They also showed that VASP is dephosphory-
lated upon formation of cell-cell contacts and that, in
conﬂuent cells, II-spectrin colocalizes with nonphosphor-
ylated VASP at cell-cell junctions (29). The exact details of
how VASP phosphorylation at Ser-157 or Ser-239 controls
one or more of these steps remain to be worked out. Even
so, the observation that different cell types contain various
clampins and their respective membrane-docking proteins
is likely to explain why VASP phosphorylation can either
stimulate or suppress cell crawling and actin-based cell
shape changes in a manner depending on cell type and/or
culture conditions.
VASP is also the most abundant platelet and endothelial
protein phosphorylated by PKG in NO signaling pathways,
and, as noted above, this cytoskeletal adaptor protein is
also a PKA substrate. Three serine/threonine phosphory-
lation sites within VASP play roles resulting in the inhibi-
tion of platelet aggregation and focal adhesion assembly
(30,31). In this study, we demonstrated that CO can also
regulate VASP phosphorylation, and we directly compare
CO and NO effects in EPCs, platelets, and microvascular
endothelial cells. We found that CO pretreatment can
similarly stimulate EPC migration (Fig. 1) and phosphor-
ylation of VASP’s Ser-157, whereas NO exposure results in
Ser-239 phosphorylation.
While we did not perform direct measurements of CO
levels in our experiments, we did use CO concentrations
that are achievable in vivo in physiological conditions and
previously used by investigators (32,33). Endogenous CO
has been reported to be generated in many cell types, and
the amount of CO released via the heme oxygenase
reaction can reach up to 12 ml/day (16 mol  l
1  h
1)
(32). Previous studies have reported that tissues can
produce 0.1–100 mol/l CO in vivo from the HO reaction
(33); it is therefore quite reasonable to believe that sufﬁ-
cient levels of HO-1 are present in cells to provide sufﬁ-
cient levels of CO, explaining our observed changes in
VASP phosphorylation.
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FIG. 5. NO exposure results in reduced VASP Ser-239 phosphorylation
in diabetic CD34
 cells compared with control cells. The extent of
phosphorylation was determined by FACS analysis on CD34
 cells from
two diabetic subjects (DA [diabetic donor A] and DB [diabetic donor
B]) and cells from a nondiabetic subject (Control [normal donor]).
Values represent means  SD. *P < 0.05.
FIG. 4. CO- and NO-mediated VASP redistribution in HMECs. HMECs,
cultured on ﬁbronectin-coated coverslips, were treated with CO and
NO donors as described in the legend to Fig. 1. A and B: Low- and
high-power images of untreated cells showing uniform VASP localiza-
tion on actin ﬁlaments throughout the cytoplasm. C and D: Low- and
high-power images showing CO-induced VASP redistribution to ﬁlopo-
dia at the leading edge of microvascular endothelial cells. E and F: Low-
and high-power images showing NO-induced redistribution of VASP to
ﬁlopodia. Representative results from three independent experiments
are shown. Green, VASP; blue, DAPI (nuclei). Scale bars  25 m.
(Please see http://dx.doi.org/10.2337/db08-0381 for a high-quality digi-
tal representation of this ﬁgure.)
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endothelial cells with NO or CO donors, VASP was readily
redistributed to the peripheral membrane and ﬁlipodia
(Fig. 4). Thus, with regard to VASP localization, our data
suggest that CO and NO may both have critical roles in
vascular cell dynamics, and CO may have important con-
tributions at low NO bioavailability, a condition already
known to occur in diabetes. Our studies clearly indicate
that both vasoactive gases promote cytoskeletal changes
through site- and cell type-speciﬁc VASP phosphorylation
and that responses to NO and CO are blunted in diabetes.
While the migratory deﬁciency seen in diabetic EPCs
could be overcome by exogenous NO (13), exogenous NO
did not result in phosphorylation and redistribution of
VASP in mature endothelial cells cultured in high glucose
conditions. This defect can be viewed as “diabetes-in-
duced NO resistance.”
What also becomes apparent from the present study is
that exposure of cells to NO or CO can greatly alter VASP
recruitment to the leading edge with consequential effects
on cell motility. Perhaps even more signiﬁcant, in the
context of diabetes, is that culturing endothelial cells at
high glucose conditions that mimic diabetes results in
motility defects that can be traced, at least in part, to
altered VASP phosphorylation. We therefore postulate that
these defects contribute to reduced vascular repair and
tissue perfusion.
Both heme oxygenases generate CO, but they do so with
very different kinetics (34,35); HO-1 is induced by oxidants
such as hydrogen peroxide, UV radiation, and proinﬂam-
FIG. 6. Cell culture under high glucose (25 mmol/l) conditions attenuates CO- and NO-mediated VASP redistribution in HMECs. A: Untreated cells
showing uniform VASP immunoreactivity along the actin ﬁlaments distributed throughout the cytoplasm. B: CO-induced VASP redistribution to
leading-edge ﬁlopodia, albeit to an extent less than that observed at normoglycemic conditions (compare image with Fig. 3 graph). C: Less
extensive VASP redistribution to ﬁlopodia in the presence of NO. Cells cultured for a week in 25 mmol/l glucose-supplemented medium on
ﬁbronectin-coated coverslips were either left untreated or treated with NO or CO (see legend to Fig. 1 for details) for 15 min before ﬁxation and
immunohistochemistry. Representative results from a minimum of three independent experiments are shown. Green, VASP; blue, DAPI (nuclei).
Scale bar  25 m. (Please see http://dx.doi.org/10.2337/db08-0381 for a high-quality digital representation of this ﬁgure.)
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FIG. 7. Cell culture under high glucose (25 mmol/l) conditions blunts CO- and NO-mediated VASP phosphorylation in HMECs. HMECs were
cultured in low (5.5 mmol/l) or high (25 mmol/l) glucose for 1 week, as described in RESEARCH DESIGN AND METHODS, before treatment with NO or
CO donor at 37°C for 1 or 15 min (see legend to Fig. 1 for details). Cells were harvested in extraction buffer, and equal quantities of total protein
were separated by SDS-PAGE, followed by transfer to nitrocellulose membrane and immunoblotting for VASP phosphorylation site determination
and quantitative analysis (normalized to total VASP as a loading control). Basal levels represent no treatment in low glucose at 1 min.
Representative results from three independent experiments are shown. Values represent means  SD. *P < 0.05.
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DIABETES, VOL. 57, SEPTEMBER 2008 2493matory cytokines and by growth factors, hemodynamic or
shear stress, heat shock, and even by NO (3). Endothelial
cells derived from either the micro- or macrovasculature
(36) responded equally to CO and NO, reﬂecting the key
roles of both HO-1 and endothelial NO synthase through-
out in the entire vasculature. In contrast, platelets do not
respond to CO, perhaps reﬂective of the low levels of heme
oxygenase in adult platelets (37). By altering HO-1 and
NOS gene expression, hypoxia potentially modulates the
availability of these gaseous second messengers. Thus,
ﬂuxes in the CO and NO generation during hypoxic stress
are likely to have dramatic consequences on the regulation
of vascular functions such as dilation, expression of
vasomodulators, inhibition of platelet aggregation, and
smooth muscle cell proliferation (38). Although the ﬁnd-
ings in this report support a role for CO sufﬁcing for NO in
promoting vascular cell migration, the signaling action of
CO results in the phosphorylation of different VASP sites
than NO. Furthermore, we demonstrate that, while both
vasoactive gases promote cytoskeletal changes through
site- and cell type–speciﬁc VASP phosphorylation, these
responses are blunted in diabetes and may be responsible
for the altered vascular repair and tissue perfusion asso-
ciated with diabetic vascular complications.
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